or Try an Advanced Search...

    Technical Analysis for BTTX - Better Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.01 51.33% 0.00
    BTTX closed down 31.82 percent on Tuesday, June 25, 2024, on 34 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical BTTX trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 52.00%
    Fell Below 50 DMA Bearish 52.00%
    180 Bearish Setup Bearish Swing Setup 52.00%
    Wide Bands Range Expansion 52.00%
    Gapped Down Weakness 52.00%
    Crossed Above 20 DMA Bullish 3.64%
    Wide Bands Range Expansion 3.64%
    Gapped Up Strength 3.64%
    Lower Bollinger Band Touch Weakness 3.64%
    20 DMA Resistance Bearish 35.71%
    Older End-of-Day Signals for BTTX ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 6 hours ago
    10 DMA Support about 6 hours ago
    50 DMA Support about 6 hours ago
    50 DMA Resistance about 7 hours ago
    20 DMA Resistance about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    BTTX Chart by TradingView
    Basic chart:

    Profile

    Better Therapeutics, Inc. Description

    Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Disease Health Sciences Diabetes FDA Health Informatics Heart Disease Healthcare Costs Behavior Modification Cognitive Behavioral Therapy Digital Therapeutics

    Is BTTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 14 Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
    Mar 5 Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
    Mar 4 Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
    Mar 1 Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Feb 20 Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
    Feb 6 Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
    Jan 18 David Perry Bought 8.6% More Shares In Better Therapeutics
    Jan 17 Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
    Jan 2 Better Therapeutics applies for FDA breakthrough designation for NASH device
    Jan 2 Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
    See more BTTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.35
    52 Week Low 0.005
    Average Volume 572,431
    200-Day Moving Average 0.21
    50-Day Moving Average 0.01
    20-Day Moving Average 0.01
    10-Day Moving Average 0.01
    Average True Range 0.00
    RSI (14) 35.06
    ADX 11.23
    +DI 16.10
    -DI 17.87
    Chandelier Exit (Long, 3 ATRs) 0.00
    Chandelier Exit (Short, 3 ATRs) 0.02
    Upper Bollinger Bands 0.01
    Lower Bollinger Band 0.01
    Percent B (%b) 0.02
    BandWidth 61.68
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram 0.0009
    Fundamentals Value
    Market Cap 407.64 Thousand
    Num Shares 54.4 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -0.01
    Price-to-Sales 49559.41
    Price-to-Book 2.29
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.01
    Resistance 3 (R3) 0.01 0.01 0.01
    Resistance 2 (R2) 0.01 0.01 0.01 0.01
    Resistance 1 (R1) 0.01 0.01 0.01 0.01 0.01
    Pivot Point 0.01 0.01 0.01 0.01 0.01
    Support 1 (S1) 0.01 0.01 0.01 0.01 0.00
    Support 2 (S2) 0.00 0.01 0.00 0.00
    Support 3 (S3) 0.00 0.00 0.00
    Support 4 (S4) 0.00